Drug
Nintedanib (OFEV®)
Status:
To Patients
Condition:
Myositis ILD
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Nintedanib (OFEV®) is an anti-fibrotic drug that is approved to treat chronic fibrosing ILD with a progressive phenotype in the United States. Chronic fibrosing ILD with a progressive phenotype encompasses a group of fibrotic lung diseases caused by different underlying diseases or conditions, including autoimmune ILD, hypersensitivity pneumonitis and idiopathic nonspecific interstitial pneumonia. In clinical trials, nintedanib has been shown to slow the progression of lung function decline in this patient population.
Study Purpose
This research study will evaluate the safety and how well the study drug, nintedanib, improves symptoms in participants with myositis-associated interstitial lung disease (MA-ILD).